Chicago, USA: June 3, 2025 -- Altis Labs, Inc. (“Altis”) is announcing results presented at The American Society of Clinical Oncology Annual Meeting 2025: in Bayer’s randomized controlled Phase 3 NExUS trial in advanced non-small cell lung cancer, IPRO-Δ predicts OS more accurately than RECIST SLD at Week 13.
The analysis used baseline and week-13 CT scans from 165 lung cancer patients enrolled in the NExUS trial to compare IPRO-Δ, Altis’ AI-derived survival score, with traditional RECIST assessment including percent change in the sum of longest diameters (ΔSLD).
Key findings include:
-IPRO-Δ had a greater association with OS (HR=1.72, 95% CI: 1.38-2.15) than ΔSLD (HR=1.14, 95% CI: 0.94-1.38)
-IPRO-Δ groups yielded larger OS differences than RECIST-based response categories (PR, SD, PD).
Altis trained IPRO-Δ to predict survival from radiology scans using its proprietary, multimodal database spanning 200,000+ cancer patients with longitudinally linked imaging, clinical, molecular, treatment, and 500,000+ patient years of outcomes data. When applied to clinical trial data, IPRO-Δ offers drug developers a novel measure to improve patient stratification and enhance estimation of treatment effect.
Access the abstract here.
About Altis Labs
Altis Labs is the computational imaging company accelerating clinical trials with AI.
Altis has created the industry's largest real-world Imaging, Clinical, and Outcomes database – comprising over 210 million cancer patient images linked to associated demographic, diagnostic, molecular, treatment, and survival information. Deep learning models trained on rwICO can generate profound insights beyond tumor measurements that make up reductionist criteria like RECIST 1.1, yielding greater association with overall survival.
Top 20 biopharma sponsors apply our deep learning models to their clinical trial imaging data to unlock powerful insights. Our models instantaneously generate Imaging-based Prognostication (IPRO) scores and thousands of Spatial Imaging Biomarkers (SIBs) from each scan, which Sponsors can combine for analysis with other data modalities such as ctDNA. These insights are being explored by clinical development teams to quantify treatment effects earlier in order to design more successful clinical trials.
Our multi-disciplinary team is on a mission to help get the most effective novel treatments to patients sooner. Altis is proudly headquartered in Toronto, ON.